Prognostic effect of systemic immune-inflammation index (SII) in 987 patients with advanced/metastatic urinary tract carcinoma (mUTC) treated with atezolizumab in the real-world global SAUL study

Autor: Mego, M., Huddart, R. A., Voortman, J., Ong, M., Gedye, C., Gurney, H., Fay, A. P., Bamias, A., Mellado Gonzalez, B., Loriot, Y., Merseburger, A. S., Castellano Gauna, D., de Ducla, S., Pavlova, J., Fear, S., Sternberg, C. N.

Publikováno v: Annals of Oncology, 31, S591-S591. Oxford University Press
Mego, M, Huddart, R A, Voortman, J, Ong, M, Gedye, C, Gurney, H, Fay, A P, Bamias, A, Mellado Gonzalez, B, Loriot, Y, Merseburger, A S, Castellano Gauna, D, de Ducla, S, Pavlova, J, Fear, S & Sternberg, C N 2020, ' Prognostic effect of systemic immune-inflammation index (SII) in 987 patients with advanced/metastatic urinary tract carcinoma (mUTC) treated with atezolizumab in the real-world global SAUL study ', Annals of Oncology, vol. 31, pp. S591-S591 . https://doi.org/10.1016/j.annonc.2020.08.838

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::24d6545c8ec7c5acc66ba6e2ec8909b4
https://research.vumc.nl/en/publications/87c55a6e-4faf-48ed-aea2-27cb08420fe9

Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract

Autor: Sternberg, C.N. Loriot, Y. James, N. Choy, E. Castellano, D. Lopez-Rios, F. Banna, G.L. De Giorgi, U. Masini, C. Bamias, A. Garcia del Muro, X. Duran, I. Powles, T. Gamulin, M. Zengerling, F. Geczi, L. Gedye, C. de Ducla, S. Fear, S. Merseburger, A.S.

Background: Atezolizumab, a humanised monoclonal antibody targeting PD-L1, is approved for locally advanced/metastatic urothelial carcinoma. SAUL evaluated atezolizumab in a broader, pretreated population, including patients ineligible for the pivota

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::38a5c318e70aba4237a50a6f72e251a8
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3105899

Safety and Efficacy of Atezolizumab in Understudied Populations with Pretreated Urinary Tract Carcinoma: Subgroup Analyses of the SAUL Study in Real-World Practice.

Autor: Merseburger AS; Department of Urology, Campus Lübeck, University Hospital Schleswig-Holstein, Lübeck, Germany., Castellano D; Medical Oncology Service, Hospital Universitario 12 de Octubre, Madrid, Spain., Powles T; Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St Bartholomew's Hospital, London, United Kingdom., Loriot Y; Department of Cancer Medicine and INSERM U981, Université Paris-Sud, Université Paris-Saclay, Gustave Roussy, Villejuif, France., Retz M; Rechts der Isar Medical Center, Technical University of Munich, Munich, Germany., Voortman J; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands., Huddart RA; Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, United Kingdom., Gedye C; Calvary Mater Newcastle, Waratah, Australia., Van Der Heijden MS; The Netherlands Cancer Institute, Amsterdam, The Netherlands., Gurney H; Macquarie University, Sydney, Australia., Ong M; The Ottawa Hospital Cancer Center, Ottawa, Canada., de Ducla S; F. Hoffmann-La Roche Ltd, Basel, Switzerland., Pavlova J; F. Hoffmann-La Roche Ltd, Basel, Switzerland., Fear S; F. Hoffmann-La Roche Ltd, Basel, Switzerland., Sternberg CN; San Camillo and Forlanini Hospitals, Rome, Italy (present address: Englander Institute for Precision Medicine, Weill Cornell Medicine, Meyer Cancer Center, New York, USA).

Publikováno v: The Journal of urology [J Urol] 2021 Aug; Vol. 206 (2), pp. 240-251. Date of Electronic Publication: 2021 Apr 09.

927P - Clinical outcomes by sex with atezolizumab (atezo) monotherapy in patients (pts) with locally advanced/metastatic urothelial carcinoma (mUC)

Autor: Hoffman-Censits, J., Rosenberg, J.E., van Der Heijden, M., Dreicer, R., Perez Gracia, J.L., Petrylak, D.P., Retz, M.M., Sabbatini, R., Naglieri, E., Caserta, C., Maruzzo, M., Iacovelli, R., Galli, L., McDermott, R., Morales Barrera, R., Bonfill, T., De Ducla, S., Ding, B., Linsenmeier, J., Sternberg, C.N.

Publikováno v: In Annals of Oncology October 2019 30 Supplement 5:v372-v373

Safety and efficacy of atezolizumab in patients with autoimmune disease: Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma.

Autor: Loriot Y; Department of Cancer Medicine and INSERM U981, Université Paris-Sud, Université Paris-Saclay, Gustave Roussy, Villejuif, France. Electronic address: yohann.loriot@gustaveroussy.fr., Sternberg CN; San Camillo and Forlanini Hospitals, Rome, Italy; Weill Cornell Medicine, New York, NY, USA. Electronic address: cns9006@med.cornell.edu., Castellano D; Medical Oncology Service, Hospital Universitario 12 de Octubre, Madrid, Spain. Electronic address: cdanicas@hotmail.com., Oosting SF; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. Electronic address: s.oosting@umcg.nl., Dumez H; Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium. Electronic address: herlinde.dumez@uzleuven.be., Huddart R; Institute of Cancer Research and Royal Marsden NHS Trust, Sutton, UK. Electronic address: Robert.Huddart@icr.ac.uk., Vianna K; Centro Integrado de Oncologia de Curitiba (CIONC), Curitiba, Brazil. Electronic address: kcmvianna@yahoo.com.br., Alonso Gordoa T; Medical Oncology Department, Hospital Universitario Ramon y Cajal, Madrid, Spain. Electronic address: teressalonso25@gmail.com., Skoneczna I; Szpital św. Elżbiety, Mokotowskie Centrum Medyczne, Warsaw, Poland. Electronic address: iwona.skoneczna@szpitalse.pl., Fay AP; Oncoclínicas Group, PUCRS School of Medicine, Porto Alegre, Brazil. Electronic address: andrepfay@gmail.com., Nolè F; Medical Oncology Division of Urogenital and Head & Neck Tumours, IEO, European Institute of Oncology IRCCS, Milan, Italy. Electronic address: franco.nole@ieo.it., Massari F; Division of Oncology, Sant'Orsola-Malpighi Hospital, Bologna, Italy. Electronic address: francesco.massari@aosp.bo.it., Brasiuniene B; National Cancer Institute, Vilnius, Lithuania. Electronic address: birute.brasiuniene@nvi.lt., Maroto P; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. Electronic address: jmaroto@santpau.cat., Fear S; F Hoffmann-La Roche Ltd, Basel, Switzerland. Electronic address: simon.fear@roche.com., Di Nucci F; Genentech, Inc., South San Francisco, CA, USA. Electronic address: di-nucci.flavia@gene.com., de Ducla S; F Hoffmann-La Roche Ltd, Basel, Switzerland. Electronic address: sabine.de_ducla@roche.com., Choy E; CREATE Centre, Section of Rheumatology, Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK. Electronic address: choyeh@cardiff.ac.uk.

Publikováno v: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2020 Oct; Vol. 138, pp. 202-211. Date of Electronic Publication: 2020 Sep 06.